The TEAMMATE (Tacrolimus/Everolimus vs. Tacrolimus/MMF in pediatric heart transplant recipients using the MATE Score) trial is the first multicenter randomized trial designed to address key scientific questions in the field of pediatric heart transplantation.
The trial, which is a partnership between Boston Children’s Hospital and Stanford Children’s Hospital, is currently enrolling children and is about 75 percent full. However, there is a strong need for more transplant recipients, and in particular teens, to participate, according to Kevin P. Daly, MD, an attending with Boston Children’s Department of Cardiology who is helping to lead the TEAMMATE effort.
